Table 4.
Correlation analysis between IRS1 mRNA expression and quantitative phenotypes.
| Quantitative trait | N* | Total cohort (N = 60) | Lean (N = 23) | Obese (N = 34) | |||
|---|---|---|---|---|---|---|---|
| mean IRS1 mRNA expression in | |||||||
| SAT | OVAT | SAT | OVAT | SAT | OVAT | ||
| SAT/OVAT | |||||||
| total – lean – obese | |||||||
| Weight | 40/32 – 19/14 – 19/17 | 0.270a [0.179]b | 0.239 [−0.214] | 0.663 [0.107] | 0.464 [−0.213] | 0.473 [0.175] | 0.451 [−0.196] |
| Visceral fat area (cm²) | 34/27 – 19/14 – 13/12 | 0.260 [−0.198] | 0.058 [0.370] | 0.229 [−0.289] | 0.474 [0.209] | 0.201 [−0.379] | 0.255 [0.357] |
| Subcutanoues fat area (cm²) | 34/27 – 19/14 – 13/12 | 0.890 [0.025] | 0.249 [−0.230] | 0.842 [0.049] | 0.899 [−0.037] | 0.494 [0.209] | 0.208 [−0.392] |
| CT-ratio (OVAT/SAT fat area) | 34/27 – 19/14 – 13/12 | 0.713 [−0.066] | 0.866 [0.034] | 0.943 [0.018] | 0.455 [0.218] | 0.803 [0.077] | 0.779 [0.091] |
| BMI kg/m2 | 40/32 – 19/14 – 19/17 | 0.274 [−0.177] | 0.236 [−0.216] | 0.065 [0.432] | 0.605 [0.152] | 0.344 [−0.230] | 0.248 [−0.297] |
| Waist circumference (cm) | 34/27 – 19/14 – 13/12 | 0.701 [−0.068] | 0.696 [−0.079] | 0.391 [−0.209] | 0.681 [−0.121] | 0.873 [0.049] | 0.795 [−0.084] |
| Hip circumference (cm) | 34/27 – 19/14 – 13/12 | 0.926 [0.017] | 0.583 [−0.111] | 0.586 [0.133] | 0.543 [−0.178] | 0.845 [0.060] | 0.430 [−0.252] |
| Waist-to-hip ratio | 34/27 – 19/14 – 13/12 | 0.598 [−0.094] | 0.854 [−0.037] | 0.057 [−0.444] | 0.899 [0.037] | 0.721 [0.110] | 0.914 [−0.035] |
| Body fat (%) | 23/18 – 11/8 – 11/10 | 0.511 [−0.144] | 0.829 [−0.055] | 0.484 [0.236] | 0.823 [−0.095] | 0.650 [0.155] | 0.881 [0.055] |
| Fasting plasma glucose (mmol/l) | 40/32 – 19/14 – 19/17 | 0.046 [−0.317] | 0.655[−0.082] | 0.046 [−0.463] | 0.840 [−0.059] | 0.088 [−0.402] | 0.866 [−0.044] |
| 2 hr OGTT plasma glucose (mmol/l) | 25/17 – 15/8 – 8/8 | 0.303 [−0.215] | 0.135 [0.377] | 0.023 [−0.582] | 0.911 [0.048] | 0.352 [0.381] | 0.047 [0.714] |
| Fasting plasma Insulin (pmol/l) | 38/29 – 19/13 – 17/15 | 0.282 [−0.179] | 0.190 [0.251] | 0.367 [−0.219] | 0.972 [0.011] | 0.593 [−0.140] | 0.405 [0.232] |
| HbA1c (%) | 39/31 – 19/14 – 18/16 | 0.382 [−0.144] | 0.763 [0.056] | 0.178 [−0.323] | 0.615 [0.147] | 0.576 [−0.141] | 0.854 [0.050] |
| HDL cholesterol (mmol/l) | 27/22 – 15/11 – 10/10 | 0.765 [0.060] | 0.334 [−0.216] | 0.820 [0.064] | 0.160 [−0.455] | 0.651 [−0.164] | 0.934 [−0.030] |
| LDL cholesterol (mmol/l) | 27/23 – 15/12 – 10/10 | 0.947 [0.013] | 0.477 [0.156] | 1.000 [0.000] | 0.245 [0.364] | 0.726 [−0.127] | 0.446 [0.273] |
| Triglycerides (mmol/l) | 22/18 – 11/8 – 10/9 | 0.393 [−0.191] | 0.705 [0.096] | 0.937 [0.027] | 0.823 [−0.095] | 0.934 [0.030] | 0.668 [0.167] |
| Adiponectin (µg/ml) | 26/21 – 12/9 – 13/12 | 0.350 [0.191] | 0.475 [−0.165] | 0.880 [−0.049] | 0.460 [−0.283] | 0.061 [0.533] | 0.319 [−0.315] |
all subjects representing methylation and expression data in either SAT (N = 40) or OVAT (N = 32) have been included while N* = subjects in SAT/OVAT per group (total – lean –obese); overweight subgroup was excluded due to N = 3; WHO classification: lean≥18; <25 kg/m²; <30 kg/m²obese≥ 30 kg/m²; SAT (subcutaneous adipose tissue); OVAT (omental visceral adipose tissue), a = P-value. P-values were calculated using bivariate Spearman correlation analysis (adjusted for age, sex and BMI (except for BMI) by calculating standardized residuals); nominal significant P-values are highlighted in bold. b = beta (ß; effect size and direction) BMI = body mass index; OGTT = oral glucose tolerance test; HDL = high density lipoprotein cholesterol; LDL = low density lipoprotein cholesterol.